1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). (December 2022) - Felip, E.; Srivastava, M.; Reck, M.; Wakelee, H.; Altorki, N.K.; Vallieres, E.; Liersch, R.; Harada, M.; Tanaka, H.; Hamm, J.T.; McCune, S.; Bennett, E.; et al.